Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02337205
Recruitment Status : Completed
First Posted : January 13, 2015
Last Update Posted : July 6, 2018
Sponsor:
Information provided by (Responsible Party):
Athenex, Inc.

Tracking Information
First Submitted Date  ICMJE January 5, 2015
First Posted Date  ICMJE January 13, 2015
Last Update Posted Date July 6, 2018
Study Start Date  ICMJE December 2014
Actual Primary Completion Date March 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 8, 2015)
  • Overall safety and tolerability assessment as determined by laboratory, adverse event (AE) and serious adverse event (SAE) information. [ Time Frame: 45 days ]
    Safety assessments will consist of determining and recording all AEs (including for both increasing and decreasing severity) and SAEs; laboratory evaluation for hematology, blood chemistry, and urine analytes; periodic measurement of vital signs and ECGs; and the performance of physical examinations as detailed in Table 3 of the protocol.
  • The amount of KX2-391 in the blood stream as determined by pharmacokinetic (PK) analysis: Cmax, Cmin, AUC0-t, AUC0-inf [ Time Frame: 7 days ]
    Individual PK data will be listed by time. Cmax, Cmin, AUC0-t, AUC0-inf will be calculated for KX2-391 to determine systemic exposure.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 8, 2015)
Actinic Keratosis (AK) lesion count [ Time Frame: 45 days ]
The AK lesion count is the investigator's assessment of the number of AK lesions in the treatment area.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis
Official Title  ICMJE A Phase 1, Single-Center, Safety, Tolerability, and Pharmacokinetic Study of KX2 391 Ointment in Subjects With Actinic Keratosis
Brief Summary This is a phase 1 study to access the safety and tolerability of KX2-391 ointment in subjects who have Actinic Keratosis. This study will also access the amount of KX2-391 drug that enters the blood stream through dermal application of the ointment.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Actinic Keratosis
Intervention  ICMJE Drug: KX2-391 Ointment
KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.
Study Arms  ICMJE Experimental: KX2-391 Ointment
Intervention: Drug: KX2-391 Ointment
Publications * Kempers S, DuBois J, Forman S, Poon A, Cutler E, Wang H, Cutler D, Fang J, Kwan R. Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results. J Drugs Dermatol. 2020 Nov 1;19(11):1093-1100. doi: 10.36849/JDD.2020.5576.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 15, 2016)
29
Original Estimated Enrollment  ICMJE
 (submitted: January 8, 2015)
16
Actual Study Completion Date  ICMJE March 2016
Actual Primary Completion Date March 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subject is at least 18 years old
  2. Subject has a clinical diagnosis of stable, clinically typical AK
  3. Subject has a treatment area on 1 dorsal forearm that in:

    Cohort 1:

    • Is one contiguous area
    • Measures 25 cm2
    • Contains 4 to 8 AK lesions that are clinically typical.

    Cohort 2:

    • Is one contiguous area
    • Measures 100 cm2
    • Contains 8 to 16 AK lesions that are clinically typical.
  4. All women of childbearing potential (WOCBP) must be:

    • Post-menopausal, defined as at least 50 years of age with amenorrhea for at least 18 months, or
    • Surgically sterile, defined as having undergone a hysterectomy, bilateral oophorectomy or tubal ligation, or otherwise incapable of pregnancy.
    • Pre or perimenopausal and practicing a highly effective method of birth control, including hormonal prescription, oral contraceptives, contraceptive injections, contraceptive patch, and intrauterine device, for the duration of their participation in the study. Abstinence and double-barrier methods do not qualify as highly effective methods of birth control.
    • All woman of child-bearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 (Visit 2) prior to administration of KX2-391 Ointment dose.

    Contraception

    • Contraception must be consistently used for at least 3 months prior to screening to 3 months after the last KX2-391 Ointment dose.
    • Male Contraception: All men who are sexually active with female partners of child bearing potential must agree to ensure their partners use highly effective contraception and therefore will not father a child from screening to 3 months after the last dose of study medication.
    • Male and Female Contraception: All men and women subjects must agree to not donate sperm or eggs or attempt conception from screening to 3 months after the last KX2-391 Ointment dose.
  5. Subject is, in the opinion of the investigator, in good general health based on medical history, physical examination, electrocardiogram (ECG), and clinical laboratory evaluations at screening.
  6. Subject has clinically acceptable liver function at screening as demonstrated by:

    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2x upper limit of normal (ULN)
    • Total bilirubin ≤ ULN
  7. No other screening laboratory test, including CBC results, considered clinically significant by the investigator
  8. Subject is not lactating
  9. Subject is willing and able to follow all study instructions and to attend all study visits
  10. Subject is able to comprehend and willing to sign an Informed Consent Form (ICF)

Exclusion Criteria:

  1. Subject has clinically atypical and/or rapidly changing AK lesions on the treatment area
  2. Subject has current systemic malignancy
  3. Subject has used any of the following systemic therapies within the specific period before Visit 1:

    • Retinoids; 180 days
    • Glucocortico-steroids; 28 days
    • Methotrexate or other anti-metabolites; 28 days
  4. Subject has used any of the following topical therapies on the treatment area within the specified period before Visit 1:

    • Retinoids; 90 days
    • Glucocortico-steroids; 14 days
  5. Subject has had any of the following of the AK therapies on the treatment area:

    Medical Therapies within 90 days (or until the site has healed, whichever is longer) before Visit 1:

    • Ingenol mebutate (eg, Picato)
    • 5-fluorouracil (eg, 5-FU; Efudex)
    • Imiquimod (eg, Aldara; Zyclara)
    • Diclofenac with or without hyaluronic acid (eg, Solaraze)
    • Moisturizer, emollients (12 hours prior to Visit 1)

    Surgical Modalities on the treatment area within 30 days (or until the site has healed following treatment, whichever is longer) before Visit 1:

    • Cryotherapy
    • Electrodesiccation
    • Laser, light (eg, photodynamic therapy, intense pulsed light) or any other energy based therapy
    • Chemical peels (eg, tricholoracetic acid)
    • Dermabrasion
    • Surgical removal (eg, curettage, excision)
  6. Subject currently has, or has experienced any of the following on the treatment area within the specified period before Visit 1:

    • A cutaneous malignancy; 180 days
    • Sunburn; 28 days
    • Body art (eg, tattoo, piercing); currently
    • Excessive tan; currently
  7. Subject has a history of sensitivity to any of the ingredients in the study medications
  8. Subject is chronically taking a known strong inhibitor of CYP3A4
  9. Subject has a skin disease (eg, atopic dermatitis, psoriasis, eczema) or condition (eg, scarring, open wounds) that, in the opinion of the investigator, might interfere with the study conduct or evaluations, or which exposes the subject to an unacceptable risk by study participation.
  10. Subject has other significant uncontrolled or unstable medical diseases or conditions that, in the opinion of the investigator, would expose the patient to unacceptable risk from study participation.
  11. Subject has participated in an investigational drug trial during which an investigational study medication was administered within 30 days before Visit 1.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02337205
Other Study ID Numbers  ICMJE KX01-AK-01-US
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Athenex, Inc.
Study Sponsor  ICMJE Athenex, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Douglas Kramer, MD Kinex Pharmaceuticals
PRS Account Athenex, Inc.
Verification Date December 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP